(Q34443749)

2 August 2017

1 reference

title

The dilemma of late-stage heart failure. Rationale for chronic parenteral inotropic support (English)

1 reference

2 August 2017

1

Mehra MR

1 reference

2 August 2017

Uber PA

2

1 reference

2 August 2017

publication date

1 November 2001

1 reference

2 August 2017

1 reference

2 August 2017

volume

19

1 reference

2 August 2017

issue

4

1 reference

2 August 2017

page(s)

627-636

1 reference

Effects of pulsed beta-stimulant therapy on beta-adrenoceptors and chronotropic responsiveness in chronic heart failure.

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2805%2970249-6

7 January 2021

Improvement of postreceptor events by metoprolol treatment in patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2805%2970249-6

7 January 2021

Decreased Catecholamine Sensitivity and β-Adrenergic-Receptor Density in Failing Human Hearts

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2805%2970249-6

7 January 2021

Beneficial effects of intermittent home administration of the inotrope/vasodilator milrinone in patients with end-stage congestive heart failure: a preliminary study

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2805%2970249-6

7 January 2021

A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2805%2970249-6

7 January 2021

Intermittent dobutamine treatment in patients with chronic refractory congestive heart failure: a randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2805%2970249-6

7 January 2021

Effect of enoximone alone and in combination with metoprolol on myocardial function and energetics in severe congestive heart failure: improvement in hemodynamic and metabolic profile.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2805%2970249-6

7 January 2021

Repeated catecholamine surges alter cardiac isomyosin expression but not protein synthesis in the rat heart

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2805%2970249-6

7 January 2021

Home inotropic therapy in advanced heart failure: cost analysis and clinical outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2805%2970249-6

7 January 2021

Morphological approach to the mechanism of heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2805%2970249-6

7 January 2021

Alteration in energetics in patients with left ventricular dysfunction after myocardial infarction: increased oxygen cost of contractility

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2805%2970249-6

7 January 2021

Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. Results of a multicenter trial. The Pimobendan Multicenter Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2805%2970249-6

7 January 2021

Progress in heart failure Management? Lessons from the real world

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2805%2970249-6

7 January 2021

The cardiovascular effects of the continuous infusion of dobutamine in patients with severe cardiac failure

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2805%2970249-6

7 January 2021

Drug-induced conditioning in congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2805%2970249-6

7 January 2021

Sustained improvement of cardiac function in patients with congestive heart failure after short-term infusion of dobutamine.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2805%2970249-6

7 January 2021

Changes in gene expression in the intact human heart. Downregulation of alpha-myosin heavy chain in hypertrophied, failing ventricular myocardium.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2805%2970249-6

7 January 2021

Inotropes in the beta-blocker era

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2805%2970249-6

7 January 2021

Intermittent inotropic therapy in an outpatient setting: a cost-effective therapeutic modality in patients with refractory heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2805%2970249-6

7 January 2021

Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor? Results of the flosequinan-ACE inhibitor trial (FACET).

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2805%2970249-6

7 January 2021

Safety and clinical utility of long-term intravenous milrinone in advanced heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2805%2970249-6

7 January 2021

Effects of milrinone on coronary hemodynamics and myocardial energetics in patients with congestive heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2805%2970249-6

7 January 2021

The economic burden of heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2805%2970249-6

7 January 2021

Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST).

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2805%2970249-6

7 January 2021

Intermittent 6-month low-dose dobutamine infusion in severe heart failure: DICE multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2805%2970249-6

7 January 2021

Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2805%2970249-6

7 January 2021

Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2805%2970249-6

7 January 2021

Sustained improvement in flow-mediated vasodilation after short-term administration of dobutamine in patients with severe congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2805%2970249-6

7 January 2021

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2805%2970249-6

7 January 2021

Inotropic agents in the treatment of heart failure: despair or hope?

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2805%2970249-6

7 January 2021

Preferences for treatment outcomes in patients with heart failure: symptoms versus survival

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2805%2970249-6

7 January 2021

Inotropic therapy for heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2805%2970249-6

7 January 2021

The effect of digoxin on mortality and morbidity in patients with heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2805%2970249-6

7 January 2021

Update of ELITE-II, BEST, CHAMP, and IMPRESS clinical trials in heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2805%2970249-6

7 January 2021

Antiarrhythmic efficacy of dipyridamole in treatment of reperfusion arrhythmias : evidence for cAMP-mediated triggered activity as a mechanism responsible for reperfusion arrhythmias

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2805%2970249-6

7 January 2021

Outpatient parenteral inotropic therapy for advanced heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2805%2970249-6

7 January 2021

10.1016/S0733-8651(05)70249-6

Identifiers

DOI

1 reference

2 August 2017

1 reference